276 related articles for article (PubMed ID: 29194852)
1. The role of sclerostin/dickkopf-1 and receptor activator of nuclear factor kB ligand/osteoprotegerin signalling pathways in the development of osteoporosis in patients with haemophilia A and B: A cross-sectional study.
Anagnostis P; Vakalopoulou S; Christoulas D; Paschou SA; Papatheodorou A; Garipidou V; Kokkoris P; Terpos E
Haemophilia; 2018 Mar; 24(2):316-322. PubMed ID: 29194852
[TBL] [Abstract][Full Text] [Related]
2. The key role of proinflammatory cytokines, matrix proteins, RANKL/OPG and Wnt/β-catenin in bone healing of hip arthroplasty patients.
Cassuto J; Folestad A; Göthlin J; Malchau H; Kärrholm J
Bone; 2018 Feb; 107():66-77. PubMed ID: 29129760
[TBL] [Abstract][Full Text] [Related]
3. Osteoprotegrin interacts with biomarkers and cytokines that have roles in osteoporosis, skin fibrosis, and vasculopathy in systemic sclerosis: A potential multifaceted relationship between OPG/RANKL/TRAIL and Wnt inhibitors.
Taylan A; Birlik M; Kenar G; Toprak B; Gundogdu B; Gurler O; Karakas B; Akıncı B; Sisman AR
Mod Rheumatol; 2019 Jul; 29(4):619-624. PubMed ID: 30001654
[No Abstract] [Full Text] [Related]
4. RANKL/OPG ratio and DKK-1 expression in primary osteoblastic cultures from osteoarthritic and osteoporotic subjects.
Corrado A; Neve A; Macchiarola A; Gaudio A; Marucci A; Cantatore FP
J Rheumatol; 2013 May; 40(5):684-94. PubMed ID: 23457386
[TBL] [Abstract][Full Text] [Related]
5. Role of Wnt/β-catenin and RANKL/OPG in bone healing of diabetic Charcot arthropathy patients.
Folestad A; Ålund M; Asteberg S; Fowelin J; Aurell Y; Göthlin J; Cassuto J
Acta Orthop; 2015; 86(4):415-25. PubMed ID: 25811776
[TBL] [Abstract][Full Text] [Related]
6. The effect of zoledronic acid on serum dickkopf-1, osteoprotegerin, and RANKL in patients with Paget's disease of bone.
Polyzos SA; Anastasilakis AD; Efstathiadou Z; Kita M; Litsas I; Avramidis A; Arsos G; Moralidis E; Gerou S; Pavlidou V; Papatheodorou A; Terpos E
Horm Metab Res; 2009 Nov; 41(11):846-50. PubMed ID: 19670154
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the Effect of Methotrexate Therapy on Bone Metabolism in Patients with Rheumatoid Arthritis.
Świerkot J; Gruszecka K; Matuszewska A; Wiland P
Arch Immunol Ther Exp (Warsz); 2015 Oct; 63(5):397-404. PubMed ID: 25837853
[TBL] [Abstract][Full Text] [Related]
8. Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.
Tsentidis C; Gourgiotis D; Kossiva L; Doulgeraki A; Marmarinos A; Galli-Tsinopoulou A; Karavanaki K
Osteoporos Int; 2016 Apr; 27(4):1631-1643. PubMed ID: 26588909
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of the bone turnover markers dickkopf-1, sclerostin, osteoprotegerin, osteopontin, osteocalcin and 25-hydroxyvitamin D in Swedish geriatric patients aged 75 years or older with a fresh hip fracture and in healthy controls.
Wanby P; Nobin R; Von SP; Brudin L; Carlsson M
J Endocrinol Invest; 2016 Aug; 39(8):855-63. PubMed ID: 26850415
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Serum sRANKL, sRANKL/OPG Ratio, and Other Bone Turnover Markers with the Estimated 10-Year Risk of Major and Hip Osteoporotic Fractures in Rheumatoid Arthritis: A Cross-Sectional Study.
Nava-Valdivia CA; Ponce-Guarneros JM; Saldaña-Cruz AM; Corona-Sanchez EG; Ramirez-Villafaña M; Perez-Guerrero EE; Murillo-Saich JD; Contreras-Haro B; Vazquez-Villegas ML; Gonzalez-Ponce F; Bonilla-Lara D; Jacobo-Cuevas H; Centeno-Valadez JD; Echeverria-Gonzalez G; Cerpa-Cruz S; Alcaraz-Lopez MF; Cardona-Muñoz EG; Salazar-Paramo M; Gonzalez-Lopez L; Gamez-Nava JI
Biomed Res Int; 2021; 2021():5567666. PubMed ID: 34497849
[TBL] [Abstract][Full Text] [Related]
11. Pulsed electromagnetic fields modulate bone metabolism via RANKL/OPG and Wnt/β-catenin pathways in women with postmenopausal osteoporosis: A pilot study.
Catalano A; Loddo S; Bellone F; Pecora C; Lasco A; Morabito N
Bone; 2018 Nov; 116():42-46. PubMed ID: 30010081
[TBL] [Abstract][Full Text] [Related]
12. Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle.
Morabito N; Gaudio A; Lasco A; Atteritano M; Pizzoleo MA; Cincotta M; La Rosa M; Guarino R; Meo A; Frisina N
J Bone Miner Res; 2004 May; 19(5):722-7. PubMed ID: 15068494
[TBL] [Abstract][Full Text] [Related]
13. Serum osteoprotegerin, RANKL, and Dkk-1 levels in adults with Langerhans cell histiocytosis.
Makras P; Polyzos SA; Anastasilakis AD; Terpos E; Kanakis G; Schini M; Papatheodorou A; Kaltsas GA
J Clin Endocrinol Metab; 2012 Apr; 97(4):E618-21. PubMed ID: 22278426
[TBL] [Abstract][Full Text] [Related]
14. Effect of recent spinal cord injury on the OPG/RANKL system and its relationship with bone loss and the response to denosumab therapy.
Gifre L; Ruiz-Gaspà S; Carrasco JL; Portell E; Vidal J; Muxi A; Monegal A; Guañabens N; Peris P
Osteoporos Int; 2017 Sep; 28(9):2707-2715. PubMed ID: 28580511
[TBL] [Abstract][Full Text] [Related]
15. Serum RANKL, osteoprotegerin (OPG) and RANKL/OPG ratio in children with systemic lupus erythematosus.
Ali R; Hammad A; El-Nahrery E; Hamdy N; Elhawary AK; Eid R
Lupus; 2019 Sep; 28(10):1233-1242. PubMed ID: 31403902
[TBL] [Abstract][Full Text] [Related]
16. Osteoprotegerin and RANKL in the pathogenesis of osteoporosis in patients with thalassaemia major.
Pietrapertosa AC; Minenna G; Colella SM; Santeramo TM; Renni R; D'Amore M
Panminerva Med; 2009 Mar; 51(1):17-23. PubMed ID: 19352306
[TBL] [Abstract][Full Text] [Related]
17. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
García-Valdecasas-Campelo E; González-Reimers E; Santolaria-Fernández F; De la Vega-Prieto MJ; Milena-Abril A; Sánchez-Pérez MJ; Martínez-Riera A; Gómez-Rodríguez Mde L
Alcohol Alcohol; 2006; 41(3):261-6. PubMed ID: 16476762
[TBL] [Abstract][Full Text] [Related]
18. Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system in patients with beta-thalassemia major.
Angelopoulos NG; Goula A; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Malaktari S; Athanasiou V; Tolis G
J Bone Miner Metab; 2007; 25(1):60-7. PubMed ID: 17187195
[TBL] [Abstract][Full Text] [Related]
19. The effect of dried plum on serum levels of receptor activator of NF-κB ligand, osteoprotegerin and sclerostin in osteopenic postmenopausal women: a randomised controlled trial.
Hooshmand S; Brisco JR; Arjmandi BH
Br J Nutr; 2014 Jul; 112(1):55-60. PubMed ID: 24780728
[TBL] [Abstract][Full Text] [Related]
20. The Role of Serum Expression Levels of Microrna-21 on Bone Mineral Density in Hypostrogenic Postmenopausal Women with Osteoporosis: Study on Level of RANKL, OPG, TGFβ-1, Sclerostin, RANKL/OPG Ratio, and Physical Activity.
Suarjana IN; Isbagio H; Soewondo P; Rachman IA; Sadikin M; Prihartono J; Malik SG; Soeroso J
Acta Med Indones; 2019 Jul; 51(3):245-252. PubMed ID: 31699948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
